Rights issue 2026

Strong investor interest gives Dicot Pharma a solid platform for future growth

Dicot Pharma has successfully completed a fundraising that will provide the company with approximately SEK 231 million before transaction costs. Interest from both existing shareholders and new investors was strong, and the offering was oversubscribed.

The strong outcome is an important endorsement of the company’s continued development and enables Dicot Pharma to advance its drug candidate LIB-01 according to plan. The next major milestone is the Phase 2b clinical trial, which is scheduled to begin in the second half of 2026.

“We are very pleased with the strong interest in the rights issue, both from existing shareholders and new investors. The result demonstrates significant confidence in Dicot Pharma and our drug development program. With this successful outcome, we can continue the development of our erectile dysfunction drug candidate, LIB-01, at full speed, with a Phase 2b trial planned to start in the second half of 2026. We look to the future with great confidence and will manage the trust we have received with the utmost care,” says Elin Trampe, CEO of Dicot Pharma.

The fundraising also strengthens the company’s preparations for upcoming stages of development. With an enhanced financial position, Dicot Pharma will continue advancing LIB-01 through clinical development and closer to future patients.